TG Shifts Focus To MS After Pausing Oncology Programs, Ukoniq Withdrawal

Company Looks Ahead To Ublituximab PDUFA Date

 
• By Alaric DeArment
TG is shifting gears to focus on developing ublituximab in multiple sclerosis • Source: Alamy

More from Business

More from Scrip